• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Artivion Inc.

    6/17/25 4:02:51 PM ET
    $AORT
    Medical/Dental Instruments
    Health Care
    Get the next $AORT alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001849615
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    ARTIVION, INC.
    SEC File Number
    001-13165
    Address of Issuer
    1655 ROBERTS BLVD NW
    KENNESAW
    GEORGIA
    30144
    Phone
    (770) 419-3355
    Name of Person for Whose Account the Securities are To Be Sold
    MARSHALL STANTON
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    15000442500.004270278506/17/2025
    NYSE


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common06/30/2024Employee Stock Purchase PlanISSUERCheckbox not checked85506/30/2024Cash
    Common02/23/2025Performance SharesISSUERCheckbox not checked337802/23/2025Not Applicable
    Common02/23/2025Restricted StockISSUERCheckbox not checked405802/23/2025Not Applicable
    Common12/31/2024Employee Stock Purchase PlanISSUERCheckbox not checked38112/31/2024Cash
    Common03/16/2024Restricted StockISSUERCheckbox not checked632803/16/2024Not Applicable

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/202599328222.65
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/2025139439619.71
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/20257701218874.74
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/2025183152113.01
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/2025176350177.62
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/20254218119882.31
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/20255153146662.11
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/202544312610.66
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/202581023057.87
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/2025126135847.33
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common06/13/202556516061.65
    MARSHALL STANTON
    1655 ROBERTS BLVD NW
    KENNESAW � GA � 30144
    Common05/09/202510548307264.29

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/17/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    03/14/2025

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Marshall Scott Stanton

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AORT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AORT

    DatePrice TargetRatingAnalyst
    6/17/2025$35.00Buy
    Canaccord Genuity
    10/23/2024$33.00Mkt Outperform
    JMP Securities
    9/27/2022$32.00 → $28.00Buy
    Lake Street
    8/8/2022$32.00Buy
    Lake Street
    3/3/2022$30.00Buy
    Stifel
    2/18/2022$39.00 → $30.00Buy
    Needham
    More analyst ratings

    $AORT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artivion to Participate in Upcoming Investor Conferences

      ATLANTA, June 3, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investors conferences. Artivion's management team will present at the upcoming Truist Securities MedTech Conference on Tuesday, June 17, 2025, at the InterContinental Boston Hotel. The Company's presentation is scheduled to begin at 8:00 a.m. ET. A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be

      6/3/25 4:10:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Closing of Transactions to Exchange $99.5 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

      ATLANTA, May 28, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of transactions related to previously announced, privately negotiated exchange agreements with certain holders (the "Holders") of its 4.250% Convertible Senior Notes due 2025 (the "Notes"). The closing transactions included the closing of an additional, privately negotiated agreement with a separate holder. Under the terms of the exchange agreements, the Holders exchanged an aggregate principal amount of approxi

      5/28/25 5:51:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Announces Agreements to Exchange $95 Million in Principal Amount of its 4.250% Convertible Notes Due 2025 for Common Stock

      ATLANTA, May 14, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE:AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it entered into separate, privately negotiated exchange agreements with certain holders of its 4.250% Convertible Senior Notes due 2025 (the "Existing Convertible Notes"). Under the exchange agreements, the company will, subject to customary closing conditions, repurchase approximately $95 million principal amount of Existing Convertible Notes in exchange for a number of shares of the company's common stock to be determined based on the trading price of the common stock over a four trading day averaging period beginning on May 15, 20

      5/14/25 4:01:00 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    SEC Filings

    See more
    • SEC Form 144 filed by Artivion Inc.

      144 - ARTIVION, INC. (0000784199) (Subject)

      6/17/25 4:02:51 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Artivion Inc.

      SD - ARTIVION, INC. (0000784199) (Filer)

      5/19/25 10:17:29 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Artivion Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ARTIVION, INC. (0000784199) (Filer)

      5/16/25 2:32:34 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP, Clinical & MD Affair Stanton Marshall S. sold $442,500 worth of shares (15,000 units at $29.50), decreasing direct ownership by 19% to 64,200 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      6/18/25 11:48:26 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, Clinical & MD Affair Stanton Marshall S. sold $743,131 worth of shares (26,132 units at $28.44), decreasing direct ownership by 25% to 79,200 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      6/16/25 8:22:21 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • SVP, General Counsel Holloway Jean F sold $253,692 worth of shares (8,748 units at $29.00), decreasing direct ownership by 5% to 178,510 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      5/27/25 5:29:35 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Semedo Anthony B. bought $53,140 worth of shares (2,100 units at $25.30), increasing direct ownership by 4% to 35,659 units (SEC Form 4)

      4 - ARTIVION, INC. (0000784199) (Issuer)

      3/5/25 4:01:01 PM ET
      $AORT
      Medical/Dental Instruments
      Health Care

    $AORT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Artivion with a new price target

      Canaccord Genuity initiated coverage of Artivion with a rating of Buy and set a new price target of $35.00

      6/17/25 7:48:51 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • JMP Securities initiated coverage on Artivion with a new price target

      JMP Securities initiated coverage of Artivion with a rating of Mkt Outperform and set a new price target of $33.00

      10/23/24 6:17:27 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care
    • Lake Street reiterated coverage on Artivion with a new price target

      Lake Street reiterated coverage of Artivion with a rating of Buy and set a new price target of $28.00 from $32.00 previously

      9/27/22 11:06:42 AM ET
      $AORT
      Medical/Dental Instruments
      Health Care